Radial access in patients with acute coronary syndrome without persistent ST-segment elevation: Systematic review, collaborative meta-analysis, and meta-regression.

[1]  I. Porto,et al.  Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy. , 2016, JACC. Cardiovascular interventions.

[2]  D. Capodanno,et al.  Radial Access Reduces Mortality in Patients With Acute Coronary Syndromes: Results From an Updated Trial Sequential Analysis of Randomized Trials. , 2016, JACC. Cardiovascular interventions.

[3]  Samin K. Sharma,et al.  Meta-Analysis of Radial Versus Femoral Access for Percutaneous Coronary Interventions in Non-ST-Segment Elevation Acute Coronary Syndrome. , 2016, The American journal of cardiology.

[4]  Deepak L. Bhatt,et al.  The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX , 2015, European heart journal.

[5]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[6]  Deepak L. Bhatt,et al.  A Call for Comprehensive Forearm Access? , 2016, The Journal of invasive cardiology.

[7]  H. Ly,et al.  The Benefits Conferred by Radial Access for Cardiac Catheterization Are Offset by a Paradoxical Increase in the Rate of Vascular Access Site Complications With Femoral Access: The Campeau Radial Paradox. , 2015, JACC. Cardiovascular interventions.

[8]  R. Wilensky,et al.  Transradial Versus Transfemoral Access in Patients Undergoing Rescue Percutaneous Coronary Intervention After Fibrinolytic Therapy. , 2015, JACC. Cardiovascular interventions.

[9]  D. Capodanno,et al.  Radial Versus Femoral Access in Invasively Managed Patients With Acute Coronary Syndrome , 2015, Annals of Internal Medicine.

[10]  G. Wells,et al.  Efficacy of Radial Versus Femoral Access in the Acute Coronary Syndrome: Is it the Operator or the Operation That Matters? , 2015, JACC. Cardiovascular interventions.

[11]  Sunil V. Rao,et al.  Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial , 2015, The Lancet.

[12]  S. Anderson,et al.  Access site practice and procedural outcomes in relation to clinical presentation in 439,947 patients undergoing percutaneous coronary intervention in the United kingdom. , 2015, JACC. Cardiovascular interventions.

[13]  M. Dalby,et al.  Radial Versus Femoral Access Is Associated With Reduced Complications and Mortality in Patients With Non–ST-Segment–Elevation Myocardial Infarction: An Observational Cohort Study of 10 095 Patients , 2014, Circulation. Cardiovascular interventions.

[14]  R. Peters,et al.  Prognostic value of access site and nonaccess site bleeding after percutaneous coronary intervention: a cohort study in ST-segment elevation myocardial infarction and comprehensive meta-analysis. , 2014, JACC. Cardiovascular interventions.

[15]  S. Yusuf,et al.  Procedural volume and outcomes with radial or femoral access for coronary angiography and intervention. , 2014, Journal of the American College of Cardiology.

[16]  S. Anderson,et al.  Baseline bleeding risk and arterial access site practice in relation to procedural outcomes after percutaneous coronary intervention. , 2013, Journal of the American College of Cardiology.

[17]  Byung Ok Kim,et al.  The Impact of Vascular Access for In-Hospital Major Bleeding in Patients with Acute Coronary Syndrome at Moderate- to Very High-Bleeding Risk , 2013, Journal of Korean medical science.

[18]  A. Kastrati,et al.  Prognostic Value of Access and Non–Access Sites Bleeding After Percutaneous Coronary Intervention , 2013, Circulation. Cardiovascular interventions.

[19]  Deepak L. Bhatt,et al.  Adoption of Transradial Percutaneous Coronary Intervention and Outcomes According to Center Radial Volume in the Veterans Affairs Healthcare System: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program , 2013, Circulation. Cardiovascular interventions.

[20]  M. Matheny,et al.  Risk‐Treatment Paradox in the Selection of Transradial Access for Percutaneous Coronary Intervention , 2013, Journal of the American Heart Association.

[21]  Sunil V. Rao,et al.  Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. , 2013, American heart journal.

[22]  J. Messenger,et al.  Clinical ResearchInterventional CardiologyThe Prevalence and Outcomes of Transradial Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: Analysis From the National Cardiovascular Data Registry (2007 to 2011) , 2013 .

[23]  Sunil V. Rao,et al.  Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. , 2012, Journal of the American College of Cardiology.

[24]  S. Pocock,et al.  Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI , 2011, JACC. Cardiovascular interventions.

[25]  S. Yusuf,et al.  Impact of transradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[26]  Sunil V. Rao,et al.  Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. , 2011, JACC. Cardiovascular interventions.

[27]  A. Stang.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[28]  B. Gersh,et al.  Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[29]  G. Ambrosio,et al.  Arterial access-site-related outcomes of patients undergoing invasive coronary procedures for acute coronary syndromes (from the ComPaRison of Early Invasive and Conservative Treatment in Patients With Non-ST-ElevatiOn Acute Coronary Syndromes [PRESTO-ACS] Vascular Substudy). , 2009, The American journal of cardiology.

[30]  Salim Yusuf,et al.  Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. , 2009, American heart journal.

[31]  R. Califf,et al.  Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[32]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[33]  S. Thompson,et al.  How should meta‐regression analyses be undertaken and interpreted? , 2002, Statistics in medicine.

[34]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[35]  C H Schmid,et al.  An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. , 1998, Statistics in medicine.

[36]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.